Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study of the Effect of First Line Treatment With Bevacizumab in Combination With Capecitabine and Oxaliplatin on Progression-free Survival in Patients With Metastatic Cancer of the Colon and Rectum

NCT01399190 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01399190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01399190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study of the Effect of First Line Treatment With Bevacizumab in Combination With Capecitabine and Oxaliplatin on Progression-free Survival in Patients With Metastatic Cancer of the Colon and Rectum
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
July 31, 2011
Completion date
February 28, 2014
Enrollment
68 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer